There are multiple factors influencing treatment decisions in a changing treatment landscape, including guidelines, experience, evidence, progonosis, lifestyle, side effect concerns, and preferences. And as treatments evolve, patients and families require timely and up-to-date education about treatment and possible adverse events prior to initiation. As the amount of detailed data on maintenance immunotherapy regimens in 1L mUC can be overwhelming to some patients, it is imperative that clinicians are able to condense the data enough to make it palatable but so that it still informs patients, and to focus on management strategies.
The final episode of this CMEOCast podcast series on providing the best care for patients with mUC focuses on helping clinicians stay abreast of the evolving evidence for maintenance immunotherapy regimens, providing patients with education that will empower them to be stakeholders in their care, and considering patient perspectives and preferences as a part of shared decision-making, in order to choose the optimal evidence-based course of treatment.
At the end of this CME/CE activity, participants should be able to evaluate the efficacy and safety data for maintenance immunotherapy regimens in 1L MUC to employ it in discussions with patients in order to choose the optimal, evidence-based course of treatment.
Supported by an educational grant from Pfizer Inc. and EMD Serono, Inc.
Oncologists, PAs, nurse practitioners, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Petrylak reports that he receives grants from Ada Cap (Advanced Accelerator Applications); Agensys, Inc.; *Astellas Pharma US, Inc.; AstraZeneca; *Bayer; BioXcel Therapeutics, Inc.; Bristol-Myers Squibb Company; Clovis Oncology; Eisai Inc.; * Eli Lilly and Company; *Endocyte; Genentech, Inc.; *Innocrin Pharmaceuticals Inc.; MedImmune, Inc.; Medivation, Inc.; Merck & Co.; Mirati Therapeutics, Inc.; *Novarti; Pfizer Inc.; *Progenics Pharmaceuticals Inc.; Replimune Group Inc; Roche; *Sanofi-Aventis; and Seattle Genetics. He is a consultant for AdaCap (Advanced Accelerator Applications); Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb Company; Clovis Oncology; Eli Lilly and Company; Exelixis, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Monopteros Therapeutics, Inc.; Pfizer Inc.; Pharmacyclics; Roche; Seattle Genetics and UroGen Pharma, Inc. He held ownership interest/investmetns in Bellicum Pharmaceuticals, Inc. (sold 7/2020) and Tyme, Inc. (sold 10/2019).
*Denotes study trials that have terminated
Dr. Sonpavde reports that he receives research support from AstraZeneca; Immunomedics; QED Therapeutics, Inc.; and Sanofi. He is a consultant for AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb Company; EMD Serono, Inc.; Exelixis, Inc.; Genentech, Inc.; Immunomedics; Janssen Pharmaceuticals, Inc.; Merck & Co.; Pfizer Inc.; Sanofi; and Seattle Genetics/Astellas Pharma US, Inc. He receives other financial or material support from AstraZeneca; Bladder Cancer Center of Excellence Steering Committee; Bristol-Myers Squibb Company; Debiopharm; Editor of Elsevier Practice Update; EMD Serono, Inc.; QED Therapeutics, Inc.; Seattle Genetics; and UpToDate, Inc.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).